It has been about a month since the last earnings report for Boston Scientific (BSX) . Shares have added about 1.5% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Boston Scientific due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Boston Scientific Q1 Earnings Beat ...

Boston Scientific (BSX) is gaining traction in the emerging markets. New regulatory approvals bode well for the company’s growth. The stock carries a Zacks Rank #2 (Buy) currently.Boston Scientific continues to expand operations across different geographies outside the United States. In 2023, 41% of the company’s consolidated revenues came from international regions.Within its international regions, the company is putting additional efforts to expand its foothold in the emerging markets (defined as all coun ...

UKRAINE - 2021/06/17: In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the background. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesBoston Scientific Boston Scientific (NYSE: BSX) saw its net income expand by $0.9 billion or 145% y-o-y to $1.6 billion in 2023. This can primarily be attributed to an expansion of its operating margin and lower taxes. In this note, w ...

Shares of Boston Scientific Corporation (BSX) scaled a new 52-week high of $74.94 on May 17, before closing the session marginally lower at $74.65.Over the past year, this Zacks Rank #2 (Buy) stock has gained 40.7% against a 0.6% decline of the industry. The S&P 500 has witnessed 26.6% growth in the said time frame.Over the past five years, the company registered earnings growth of 7.3% compared with the industry’s 3.9% rise. The company’s long-term expected growth rate of 12.5% compares with the industry’s ...

Boston Scientific Corporation (BSX) recently presented favorable six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM System — the first modular cardiac rhythm management system that consists of the EMBLEM Subcutaneous Implantable Defibrillator or S-ICD System and the EMPOWER Leadless Pacemaker. The findings were concurrently published in the New England Journal of Medicine and presented at the Heart Rhythm Society's annual meeting, Heart Rhythm 2024.The recent development will ...

Additional data from APPRAISE ATP trial reinforce modular therapy approach with EMBLEM™ Subcutaneous Implantable Defibrillator and EMPOWER™ Leadless Pacemaker MARLBOROUGH, Mass., May 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System and t ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Boston Scientific (BSX) .Boston Scientific currently has an average brokerage recommendation (A ...

Boston Scientific (BSX) is gaining market share across all segments. New regulatory approvals and accretive acquisitions bode well for long-term growth. The stock carries a Zacks Rank #2 (Buy) currently.Boston Scientific is consistently gaining market share within its MedSurg segment. The Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal (GI) and pulmonary treatment options. Particularly, the company is gaining market share with its biliary fra ...

MARLBOROUGH, Mass., May 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Cheryl Pegus to its board of directors, effective immediately. Dr. Pegus has more than 25 years of clinical and business leadership experience, most recently serving as a partner at Morgan Health focused on improving the quality, affordability and equity of health care. Prior to that, Dr. Pegus was executive vice president of Health & Wellness at Walmart, president of Consumer Soluti ...

It’s not exactly an ideal time to be a stock market investor. The market is in correction territory, with many leading tech giants experiencing a pullback in prices. With that in mind, the savvy investor will want to focus on Needham price targets to steer them out of the current chaos.Needham price targets can be a reliable guide to steer you through turbulence. Needham ratings become doubly important when the market is down, with investors looking to identify resilient stocks or those with strong recovery ...